Skip to main content

XTL Biopharmaceuticals Ltd. (XTLB)

NASDAQ: XTLB · IEX Real-Time Price · USD
3.05 -0.09 (-2.87%)
Dec 3, 2021 4:00 PM EST - Market closed
Market Cap16.93M
Revenue (ttm)n/a
Net Income (ttm)-2.95M
Shares Out5.55M
EPS (ttm)-0.50
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume7,127
Open3.13
Previous Close3.14
Day's Range3.05 - 3.18
52-Week Range2.27 - 6.69
Beta0.99
Analystsn/a
Price Targetn/a
Earnings Daten/a

About XTLB

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. Its lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. XTL Biopharmaceuticals Ltd. has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies ...

IndustryBiotechnology
IPO DateSep 1, 2005
CEOJoshua Levine
CountryUnited States
Stock ExchangeNASDAQ
Ticker SymbolXTLB
Full Company Profile

Financial Performance

Financial Statements

News

Dr. Morris C. Laster Files Preliminary Proxy Statement Nominating Two Highly-Qualified Individuals For Election To Bo...

JERUSALEM, Sept. 20, 2021 /PRNewswire/ -- Dr. Morris C.

Other symbols:SCPS
2 months ago - PRNewsWire